

Evaluation of Spironolactone and Furosemide use in Hospitalized Patients with Cirrhosis and Ascites Leanne Bockstruck, PharmD Candidate; Carrie Vogler, PharmD, BCPS

4/

39

14

Background

- Ascites is the most common complication in patients with cirrhosis of the liver.
- Approximately 60% of patients with cirrhosis can develop ascites over a 10-year period, with a high mortality rate within 3 years of onset.
- The Journal of Hepatology and the European Association for the Study of Liver recommend the ratio of diuretics for pharmacologic management spironolactone 100mg: furosemide 40mg (ratio 0.4) in order to maintain normokalemia and euvolemia.

Objectives

• The objective of this study is to assess factors that impact diuretic ratios and doses among hospitalized patients with ascites due to liver cirrhosis.

Methods

Study Design:

- Retrospective, single site, chart review
- IRB Approval:
- Southern Illinois University Edwardsville Institutional Review Board

Data Source:

- Springfield Memorial Hospital in Springfield, IL from May 1, 2018- May 1, 2023
- **Study Population- Inclusion Criteria:**
- Adults 18-89 years old
- Diagnosed ascites based on documented ICD10 code: R18
- Combined use of spironolactone and furosemide or loop diuretic during hospitalization
- Hospitalization with admission >24 hours
- **Study Population- Exclusion Criteria:**
- Death during hospitalization
- Pursuing hospice care
- Diagnosed malignant ascites

Table 1: Baseline cl	naracter	ristics	
Baseline Characteristics	Total	Ratio of 0.4 During Hospitalization	Not at Ratio 0.4 During Hospitalizati
Patients, N (%)	100	48 (48)	52 (52)
Age (35-89 years), mean	66.6	63.9	69.2
Male	54	24	30
Race-White, N (%)	94	45 (47.9)	49 (52.1)
Race- African American, N	2	1	1
Race- Other, N	4	2	2
Length of Stay $(1-38 days)$, median $(IQR)^1$	6 (6)	5 (7)	6 (6)
Therapeutic Paracentesis, N (%)	52	31 (59.6)	21 (40.4)
Normal Serum Creatinine ² , N (%)	61	29 (47.5)	32 (52.5)
Potassium 3.5-5 mEq/L, N (%)	82	38 (47.5)	44 (53.7)
	Child-I	Pugh Class ³	P = 0.04
A, N (%)	11	2 (18.2)	9 (81.8)
B, N (%)	52	21 (40.4)	31 (59.6)

C, N (%) Interquartile range

² Serum Creatinine Male= 0.7-1.3mg/dL Female= 0.6-1.1 mg/dL

³ Three patients did not have a Child-Pugh score calculated; data was excluded.

34

P-value reflects comparison Child-Pugh class A versus C

Table 2: Diure	etic dosing	per patie	ent from	admissi	on t

20 (58.8)

	Admission, N	Hospitalization, N	IV*, N	Dis
Spironolactone	Dose			
>199 mg/day	4	7		
100-199 mg/day	15	26		
<100 mg/day	25	66		
Furosemide Ora	al Dose			
>80 mg/day	3	3	1	
40-80 mg/day	39	59	11	
<40mg/day	19	27	35	
Furosemide/Spi	ronolactone	Ratio (40mg/100	mg)	
>0.4	17	42	22	
0.4	18	40	11	
<0.4	65	14	67	

*IV= intravenous, IV dose converted to equivalent oral dose, during hospitalization



25

0

21

Patients were more likely to have paracentesis completed when on the recommended ratio. Acknowledgement: Thank you to Dr. Chris Herndon, PharmD for assistance with statistical analysis.

Results

 Table 3: Receipt of guideline recommended ratio of diuretics
by specific factors

	On Guideline Re			
	Yes	No	I -value	
Paracentesis Completed, N (%)				
Yes	28 (53.8)	24 (46.2)	0.027	
No	15 (31.3)	33 (68.8)		
High Volume				
Yes	10 (47.6)	11 (52.4)	0.631	
No	33 (41.8)	46 (58.2)		
Hypokalemia, N (%)				
Yes	9 (60)	6 (40)	0.168	
No	34 (40)	51 (60)		
Iean Potassium	10	10		
Level, mmol/L	T. U	7.0		
Potassium S				
Yes	21 (45.7)	25 (54.3)	0.621	
No	22 (40.7)	32 (59.3)		
an Systolic Blood essure, mmHg	119	126	0.061	
n Diastolic Blood essure, mmHg	68	71		

Limitations

Small sample size, single institution, retrospective Patients only had to be on ratio once during hospitalization to be included in the study Excluded patients on monotherapy with spironolactone or furosemide Subjectiveness of the Child-Pugh score Conclusions

Patients with ascites due to cirrhosis were less likely to be treated with the ratio of spironolactone 100mg: furosemide 40mg then alternative treatment.

Patients were more likely to receive the ratio when in Child-Pugh class C compared to class A.

There is a statistical difference between

spironolactone dosing for patients with Child-Pugh class A compared to class C.